Literature DB >> 31600840

Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute-Comprehensive Cancer Center.

Adrianne R Mallen1,2, Claire C Conley3, Mary K Townsend4, Ali Wells5, Bernadette M Boac6, Sarah Todd1,2, Anjalika Gandhi2, Michelle Kuznicki2, Bianca M Augusto3, McKenzie McIntyre3, Brooke L Fridley7, Shelley S Tworoger4, Robert M Wenham1, Susan T Vadaparampil3.   

Abstract

Germline mutations (eg, BRCA1/2) have prognostic and treatment implications for ovarian cancer (OVCA) patients. Thus, national guidelines recommend genetic testing for OVCA patients. The present study examines patterns and predictors of genetics referral in OVCA patients. Electronic medical record data were abstracted retrospectively from 557 OVCA patients treated from 1 January 2001 to 31 December 2015. Logistic regression models identified sociodemographic characteristics, disease/treatment characteristics, family history data, provider characteristics, and survival data that predicted genetics referral. Overall, 27.5% of patients received referral. Eleven variables predicting referral were selected during stepwise regression: younger age, White race, not having private insurance, professional school education, year of OVCA diagnosis, platinum sensitivity, female gynecologic oncologist, chemotherapy administered by a gynecologic oncologist, clinical trial enrollment, longer overall survival, and family history of OVCA. Genetics referral among OVCA patients was similar to rates reported nationwide. Unique predictive factors will contribute to quality improvement and should be validated at a multi-institutional level to ensure guideline concordant care is provided to all OVCA patients. Future research should identify both patient-level and provider-level factors associated with genetics referral.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990BRCA1/2; genetic counseling; genetic testing; germline mutation; ovarian cancer

Mesh:

Substances:

Year:  2019        PMID: 31600840      PMCID: PMC7322721          DOI: 10.1111/cge.13654

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  18 in total

1.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

Authors:  Da Yang; Sofia Khan; Yan Sun; Kenneth Hess; Ilya Shmulevich; Anil K Sood; Wei Zhang
Journal:  JAMA       Date:  2011-10-12       Impact factor: 56.272

2.  A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.

Authors:  Erica M Bednar; Holly D Oakley; Charlotte C Sun; Catherine C Burke; Mark F Munsell; Shannon N Westin; Karen H Lu
Journal:  Gynecol Oncol       Date:  2017-06-10       Impact factor: 5.482

3.  Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.

Authors:  Denise Uyar; Jamie Neary; Amy Monroe; Melodee Nugent; Pippa Simpson; Jennifer L Geurts
Journal:  Gynecol Oncol       Date:  2018-04-10       Impact factor: 5.482

4.  Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.

Authors:  Casey L Swanson; Amanika Kumar; Joy M Maharaj; Jennifer L Kemppainen; Brittany C Thomas; Megan R Weinhold; Kristine M Slaby; Kristin C Mara; Myra J Wick; Jamie N Bakkum-Gamez
Journal:  Gynecol Oncol       Date:  2018-02-03       Impact factor: 5.482

5.  Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.

Authors:  Mary B Daly; Robert Pilarski; Jennifer E Axilbund; Michael Berry; Saundra S Buys; Beth Crawford; Meagan Farmer; Susan Friedman; Judy E Garber; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison Kurian; Jennifer K Litton; Lisa Madlensky; P Kelly Marcom; Sofia D Merajver; Kenneth Offit; Tuya Pal; Huma Rana; Gwen Reiser; Mark E Robson; Kristen Mahoney Shannon; Elizabeth Swisher; Nicoleta C Voian; Jeffrey N Weitzel; Alison Whelan; Myra J Wick; Georgia L Wiesner; Mary Dwyer; Rashmi Kumar; Susan Darlow
Journal:  J Natl Compr Canc Netw       Date:  2016-02       Impact factor: 11.908

6.  Ovarian cancer in the United States: contemporary patterns of care associated with improved survival.

Authors:  William A Cliby; Matthew A Powell; Noor Al-Hammadi; Ling Chen; J Philip Miller; Phillip Y Roland; David G Mutch; Robert E Bristow
Journal:  Gynecol Oncol       Date:  2014-10-29       Impact factor: 5.482

7.  Pre-test genetic counseling services for hereditary breast and ovarian cancer delivered by non-genetics professionals in the state of Florida.

Authors:  S T Vadaparampil; C L Scherr; D Cragun; T L Malo; T Pal
Journal:  Clin Genet       Date:  2014-05-09       Impact factor: 4.438

8.  The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services.

Authors:  D Gareth Evans; Julian Barwell; Diana M Eccles; Amanda Collins; Louise Izatt; Chris Jacobs; Alan Donaldson; Angela F Brady; Andrew Cuthbert; Rachel Harrison; Sue Thomas; Anthony Howell; Zosia Miedzybrodzka; Alex Murray
Journal:  Breast Cancer Res       Date:  2014-09-19       Impact factor: 6.466

9.  A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.

Authors:  Heather Hampel; Robin L Bennett; Adam Buchanan; Rachel Pearlman; Georgia L Wiesner
Journal:  Genet Med       Date:  2014-11-13       Impact factor: 8.822

Review 10.  Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers.

Authors:  Claudia Marchetti; Francesca De Felice; Innocenza Palaia; Giorgia Perniola; Angela Musella; Daniela Musio; Ludovico Muzii; Vincenzo Tombolini; Pierluigi Benedetti Panici
Journal:  BMC Womens Health       Date:  2014-12-12       Impact factor: 2.809

View more
  2 in total

1.  Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.

Authors:  Jenny Lin; Ravi N Sharaf; Rachel Saganty; Danyal Ahsan; Julia Feit; Andrea Khoury; Hannah Bergeron; Eloise Chapman-Davis; Evelyn Cantillo; Kevin Holcomb; Stephanie V Blank; Ying Liu; Charlene Thomas; Paul J Christos; Drew N Wright; Steven Lipkin; Kenneth Offit; Melissa K Frey
Journal:  Gynecol Oncol       Date:  2021-05-19       Impact factor: 5.304

2.  "I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer.

Authors:  Adrianne R Mallen; Claire C Conley; Lindsay Fuzzell; Dana Ketcher; Bianca M Augusto; McKenzie McIntyre; Laura V Barton; Mary K Townsend; Brooke L Fridley; Shelley S Tworoger; Robert M Wenham; Susan T Vadaparampil
Journal:  Support Care Cancer       Date:  2020-09-25       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.